Clinical Trial Update: Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study [Phase 3]

View source ↗

Summary

Phase 3 China extension study comparing pembrolizumab plus gemcitabine/cisplatin against placebo plus gemcitabine/cisplatin as first-line treatment for biliary …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Carcinoma

Drugs mentioned

• Gemzar (gemcitabine)
• KEYTRUDA (PEMBROLIZUMAB)
• Platinol (cisplatin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Biliary Tract Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2023-12-26